Misty Dawn Shields/X
Mar 12, 2025, 11:19
Top advances of the year: Small cell lung cancer – ACS Journal Cancer
Top Advances in Small Cell Lung Cancer: A Commentary by Misty D. Shields et al.
The ACS Journal Cancer recently shared a new commentary by Misty D. Shields, Anne Chiang, and Lauren Averett Byers, highlighting the top advances of the year in small cell lung cancer (SCLC).
This in-depth article explores the latest breakthroughs in SCLC, offering insights into recent therapeutic developments and evolving treatment strategies. Shields and her co-authors provide a comprehensive analysis of key research findings that are shaping the future of SCLC management.
As the landscape of lung cancer treatment continues to evolve, this commentary serves as a valuable resource for oncologists and researchers, shedding light on promising innovations in the field.
Summary: 2024 Breakthroughs in Small Cell Lung Cancer (SCLC)
- Immunotherapy Advances: Consolidative durvalumab for limited-stage SCLC and lurbinectedin with atezolizumab for extensive-stage SCLC improved outcomes.
- New Therapies: Tarlatamab, an anti-DLL3 bispecific T-cell engager, and antibody-drug conjugates showed promise.
- Precision Medicine: Biomarker studies like SWOG S1929 and neuroendocrine subtyping in SWOG S2409 (PRISM) trial aimed to personalize treatments.
- Advocacy: The Small Cell SMASHERS group amplified support for SCLC research and patient care.
Top advances of the year: Small cell lung cancer.
Authors: Misty D. Shields, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 12, 2025, 13:13
Mar 12, 2025, 13:13
Mar 12, 2025, 13:02
Mar 12, 2025, 12:59
Mar 12, 2025, 12:51
Mar 12, 2025, 12:37
Mar 12, 2025, 11:40
Mar 12, 2025, 11:34